Gross Profit Analysis: Comparing Johnson & Johnson and Pharming Group N.V.

Pharma Giants: A Decade of Profit Growth

__timestamp	Johnson & Johnson	Pharming Group N.V.
Wednesday, January 1, 2014	51585000000	21595165
Thursday, January 1, 2015	48538000000	6590427
Friday, January 1, 2016	50205000000	11768542
Sunday, January 1, 2017	51096000000	92587038
Monday, January 1, 2018	54490000000	129203843
Tuesday, January 1, 2019	54503000000	165412447
Wednesday, January 1, 2020	54157000000	203056430
Friday, January 1, 2021	55338000000	169670071
Saturday, January 1, 2022	55394000000	188060000
Sunday, January 1, 2023	58606000000	220104000
Monday, January 1, 2024	33879000000

Unleashing the power of data

Gross Profit Trends: Johnson & Johnson vs. Pharming Group N.V.

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. Over the past decade, Johnson & Johnson has consistently demonstrated robust growth in gross profit, with a notable increase of approximately 14% from 2014 to 2023. In contrast, Pharming Group N.V. has shown a remarkable upward trajectory, with its gross profit surging by over 900% during the same period. This stark difference highlights the scale and market reach of these two companies. While Johnson & Johnson's profits are in the tens of billions, Pharming Group N.V. is steadily climbing, reflecting its growing influence in the market. The data underscores the dynamic nature of the pharmaceutical sector, where both established giants and emerging players are making significant strides.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025